期刊文献+

艾素联合异环磷酰胺治疗复发性卵巢上皮癌近期疗效观察 被引量:1

Clinical efficacy of taxotere plus ifosfamide in the recurrent ovarian epithelial carcinoma
下载PDF
导出
摘要 目的探讨艾素联合异环磷酰胺治疗复发性卵巢上皮癌的疗效和毒副作用.方法艾素75 g/m2,静滴,d1;异环磷酰胺1.5 g/m2,静滴,d2~5;美斯钠400 mg,分别于应用异环磷酰胺之后的0,4,8 h,静滴.每周期间隔21~28 d,均应用两周期以上.结果总有效率为65.4%;毒副作用主要是轻中度的骨髓抑制、恶心、呕吐、脱发等.结论艾素联合异环磷酰胺治疗复发性卵巢上皮癌有较好的疗效,毒副作用较小、可耐受. Objective To evaluate the efficacy and the side effects of taxotere (TXT) plus ifosfamide (IFO) in the recurrent ovarian epithelial carcinoma (OEC).Methods Twenty-six cases of advanced OEC with unsuccessful former treatments were treated with TXT 75 g/,^2, iv d1 ; IFO 1.5 g/m^2, iv, d2-5. Mesma 400 nag (iv) was given at 0,4,8 hours after the administration of IFO. Two or more the repeat courses were conducted with an interval 21 to 28 days. All patients were evaluated for response. Results The total response rate ( CR + PR) was 65.4%. The side effects were mild, including myelesuppression, nausea and vomiting the mild-gastrointestinal irritation. Conclusion The combination chemotherapy of MB plus IFO is a safe and effective regimen for patients with recurrent OEC and is worry of widespread use.
作者 刘军
出处 《中国肿瘤临床与康复》 2005年第5期417-418,共2页 Chinese Journal of Clinical Oncology and Rehabilitation
关键词 卵巢肿瘤 化学疗法 艾素 异环磷酰胺 Ovarian neoplasms/chemtherapy Taxotere Ifosfamide
  • 相关文献

参考文献3

  • 1Veschraegen CF,Sittisomnong T,Kudelka AP,et al.Docetaxel for patients with paclitaxel-resistant mulovarian carcinomat[J].J Clin Oncol,2000,18(14):2733-2739.
  • 2孙燕.异环磷酰胺临床研究进展[J].癌症,1992,11(3):181-183. 被引量:72
  • 3Markman M,Hakes T,Rreichmen B,et al.Ifofamide and mesna in previously treated advanced epithelial ovarian cancer:activity in platinum rresistant disease[J].J Clin Oncol,1991,10:243-248.

共引文献71

同被引文献3

  • 1Vasey P. Survival and longer-term toxicity results of the SCOTROC study: docetaxel carboplatin (DC) vs. paclitaxd-carboplatin (PC) in epithelial ovarian cancer(E(X2)[J]. Proc Am Soc Clin Oncol, 2002,86 (1):19-25.
  • 2Aravantinos G, Bafalonkos D,Fountzilas G, et al. Phase Ⅱ study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer[J]. Ann Oncol,2003,14(7) : 1094-1099.
  • 3Veschraegen C F,Sittisomnong T, Kudelka A P, et al. Docetaxel for patients with paclitaxel-resistant mulovarian carcinomat[J]. J Clin Oncol,2000,18(14):2273-2739.

引证文献1

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部